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Abstract
Angiogenesis requires the deposition of type IV
collagen by endothelial cells into the basement mem-
brane of new blood vessels. Stabilization of type IV
collagen triple helix depends on the hydroxylation of
proline, which is catalyzed by the iron-containing
enzyme prolyl hydroxylase. This enzyme, in turn, re-
quires ascorbic acid to maintain the enzyme-bound
iron in its reduced state. We hypothesized that die-
tary ascorbic acid might be required for tumor angio-
genesis and, therefore, tumor growth. Here, we show
that, not surprisingly, ascorbic acid is necessary for
the synthesis of collagen type IV by human endothelial
cells and for their effective migration and tube for-
mation on a basement membrane matrix. Further-
more, ascorbic acid depletion in mice incapable of
synthesizing ascorbic acid (Gulo– / – ) dramatically re-
stricts the in vivo growth of implanted Lewis lung
carcinoma tumors. Histopathological analyses of
these tumors reveal poorly formed blood vessels,
extensive hemorrhagic foci, and decreased collagen
and von Willebrand factor expression. Our data indi-
cate that ascorbic acid plays an essential role in tumor
angiogenesis and growth, and that restriction of
ascorbic acid or pharmacological inhibition of prolyl
hydroxylase may prove to be novel therapeutic ap-
proaches to the treatment of cancer.
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Introduction
Ascorbic acid (vitamin C) is an essential dietary requirement
in humans and other primates due to the genetic absence of
a key enzyme in ascorbic acid synthesis, L-gulono-g-lactone
oxidase [1,2]. Humans deficient in ascorbic acid develop
scurvy—a disease that came to prominence in the era of
long sea voyages and was first systematically described by
Lind [3] in 1753. Bleeding gums, hemorrhage, and ecchy-
moses, which are themajormanifestations of this deficiency,
are due to impaired collagen deposition leading to defective
blood vessel formation and repair [4].
The clinical manifestations of scurvy reflect the crucial
importance of ascorbic acid in angiogenesis and blood
vessel repair. Angiogenesis, in particular, is a prerequisite for
tumor growth in vivo. Tumors are unable to grow beyond f1
to 2 mm3 without the formation of new blood vessels, which will
deliver metabolic substrates and oxygen [5]. Effective angio-
genesis requires the deposition of mature type IV collagen in
the basement membrane of blood vessels by endothelial cells
[6]. Type IV collagen folding, in turn, is dependent on the
hydroxylation of proline by the iron-dependent enzyme prolyl
hydroxylase, which requires ascorbic acid to reduce iron to its
ferrous state for the reactivation of the enzyme [7]. These
considerations provide general support for the idea that de-
pletion of ascorbic acid might limit tumor growth by impairing
blood vessel formation and repair.
However, there are reasons to suppose that ascorbic acid
deficiency might have the opposite effect on tumor growth. For
example, ascorbic acid is also important in maintaining normal
immune function and in augmenting host immunity against
cancer [8–10]. Although early studies attributed ascorbic acid–
dependent augmentation of tumor immunity to improvement
in cytolytic functions of lymphocytes and phagocytes, the pre-
cise mechanisms have not been clearly defined [11,12]. How-
ever, in the particular case of lymphocyte function, more recent
data suggest that ascorbic acid may improve host immunity by
inhibiting T-cell apoptosis [13].
Ascorbic acid deficiency may also affect the expression of
hypoxia-inducible factor-1a (HIF-1a) in such a way as to pro-
mote tumor growth. Neoplastic cells exposed to low oxygen
respond by stabilizing HIF-1a, which acts to induce the
transcription of several mRNA transcripts that are essential
for tumor growth, including glycolytic enzymes and vascular
endothelial growth factor (VEGF). Ascorbic acid is a cofactor for
the proline hydroxylation and subsequent proteosomal degra-
dation of HIF-1a. Depletion of ascorbic acid reportedly inter-
rupts this degradation, causing high HIF-1a expression and
upregulation of several protumorigenic transcriptional tar-
gets [14]. Accordingly, dietary ascorbic acid restriction might
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enhance tumor growth by allowing increased stabilization
of HIF-1a and/or by impairing tumor immunity.
Thus, it is not clear whether ascorbic acid deficiencymight
increase or decrease tumor growth. A major impediment to
testing the importance of ascorbic acid in tumor growth has
been that mice, the most facile model for such studies, are
able to synthesize ascorbic acid and do not require dietary
vitamin C. Recently, mice bearing a homozygous deletion of
the L-gulono-g-lactone oxidase gene (Gulo/) have been
generated; like humans, they require ascorbic acid supple-
mentation to avoid manifestations of vitamin C deficiency
[15]. Plasma ascorbic acid concentrations fall to approxi-
mately 10 mM (f 1.7 ± 0.2 mg/ml ) in Gulo/ mice kept on
restricted dietary ascorbic acid for 3 to 5 weeks and, after
f 6 weeks of restriction, these animals demonstrate weight
loss and hemarthroses [15].
Using this new animal model, we examined the require-
ment of dietary ascorbic acid for the growth of highly angio-
genic Lewis lung carcinoma. Our results indicate that tumor
growth is greatly diminished in vitamin C–deficient Gulo/
mice. Tumors grown in these mice also show defective
angiogenesis and intratumoral hemorrhagic foci. Contrary
to what might be expected, however, there are no significant
effects on HIF-1a expression by tumor cells. The marked
suppression of tumor growth in these vitamin C–deficient
mice may provide a rationale for clinical trials in humans to
evaluate the effects of dietary ascorbic acid restriction on
cancer progression.
Materials and Methods
Cell Lines and Culture Conditions
Human umbilical vein endothelial cells (HUVECs) were
obtained from Cambrex (Walkersville, MD) and were grown
in culture with basal medium (EGM; Cambrex) supple-
mented with bovine brain extract, human endothelial cell
growth factor, hydrocortisone, gentamicin, amphotericin B,
and 2% fetal bovine serum (FBS) (EGM BulletKit; Cambrex).
HUVECs used for experiments were between six and eight
passages. Lewis lung carcinoma cells were obtained from
ATCC (Manassas, VA) and cultured in Dulbecco’s modified
Eagle’s medium (Invitrogen, Carlsbad, CA) supplemented
with 10% FBS (HyClone Laboratories, Logan, UT) and gen-
tamicin (Invitrogen). All cell lines were grown at 37jC in 5%
CO2. For some experiments, 0 to 200 mM L-ascorbic acid
(Sigma, St. Louis, MO) was used to supplement the growth
medium. Lewis lung carcinoma cells were exposed to hyp-
oxia by incubation for 16 hours in 1% oxygen balanced
with nitrogen and 5% CO2 in a modular incubator chamber
(Billups-Rothenburg, Del Mar, CA).
Collagen Detection by Enzyme-Linked Immunosorbent
Assay (ELISA)
HUVECs were plated at a density of 4  103 cells/well on
96-well plates (Costar Corning, Corning, NY) in EGM con-
taining 0 to 200 mM L-ascorbic acid (Sigma). For these ELISA
determinations, human placental collagen type IV (Rockland
Immunochemicals, Gilbertsville, PA) was used as a positive
control. After 1 to 10 days in culture, HUVECs were detached
with 0.25% trypsin–EDTA (Invitrogen), and the plates were
washed with Tris-buffered saline (Tris/NaCl; 50 mM Tris,
150 mM NaCl, pH 8.5). The wells were then blocked with
1% bovine serum albumin (Sigma) in phosphate-buffered
saline (PBS) for 1 hour at 37jC and washed with Tris/NaCl.
The plates were incubated with rabbit anti-human type IV
collagen (1:4000; Rockland Immunochemicals) for 2 hours
at 37jC, washed thrice with Tris/NaCl/0.05% Tween-20,
and then incubated with horseradish peroxidase (HRP)–
conjugated donkey anti-rabbit immunoglobulin (1:8000;
Rockland Immunochemicals) for 1 hour. After three washes
with Tris/NaCl/Tween-20, color development in the presence
of 2,2V-azino-bis [3-ethylbenzthiazoline-6-sulfonic acid]
(ABTS; Rockland Immunochemicals) was read with a spec-
trophotometer at 420 nm. The assay was performed in qua-
druplicate and was repeated twice.
Endothelial Tube Formation Assay
Twenty-four-well plates (Costar Corning) were coatedwith
Matrigel basement membrane matrix (250 ml/well; BD Bio-
sciences, Bedford, MA) according to the manufacturer’s
instructions and allowed to polymerize at 37jC for 60 min-
utes. HUVECs grown in culture were detached, resus-
pended in EGM, and seeded on Matrigel-coated wells (8 
104 well1) in 0 to 200 mM L-ascorbic acid. The plates were
incubated at 37jC in 5% CO2 and examined for tube forma-
tion through an inverted photomicroscope every 6 hours
for 18 hours. At 18 hours, intact tubes formed were enumer-
ated in three random fields, and representative photomicro-
graphs were taken (original magnification, 40). The assay
was performed in triplicate and repeated twice.
In Vivo Experiments
All animal experiments were conducted with the approval
of the Institutional Animal Care and Use Committee at the
University of Louisville (Louisville, KY).Gulo+/ heterozygous
breeding pairs (C57Bl6/J mice B6.129P2-Gulotm1Unc/Ucd)
were obtained from the Mutant Mouse Regional Resource
Center, and homozygous (Gulo/) mice were bred. Geno-
typing was performed using tail biopsy specimens with the
REDExtract-N-Amp Tissue PCR Kit (Sigma) and primers as
previously described [15]. All mice used in the experiments
were < 3 months of age.
Mice were weaned at 3 weeks of age onto irradiated
mouse chow (PicoLab Mouse Diet 5058; PMI Feeds, St.
Louis, MO) containing 110 mg/kg ascorbic acid and were
maintained on this diet during all experiments. Because this
amount is not sufficient to maintain a physiological concen-
tration of vitamin C inGulo/ animals [15], ascorbic acid was
supplemented in drinking water (330 mg/l L-ascorbic acid +
0.01 mM EDTA), which was changed weekly.
For initial outgrowth experiments, Gulo/ mice were
depleted of ascorbic acid by withholding supplementation in
drinking water for 4 weeks immediately after weaning and
then were randomized to continued depletion or repletion by
supplementation with 330 mg/l ascorbic acid in drinking
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water. A third group of Gulo/ mice was maintained on full
supplementation with 330 mg/l ascorbic acid before and after
tumor implantation. Each group contained 10 animals.
For studying the growth of established tumors, theGulo/
mice used were maintained on 165 mg/l ascorbic acid sup-
plementation in water for 2 weeks before starting the study.
They were then randomized either to depletion (by withholding
supplementation) or to continued supplementation at 165mg/l.
Each group contained 10 animals.
For experiments on minimal supplementation, Gulo/
mice were depleted by withholding ascorbic acid supplemen-
tation for 4 weeks immediately after weaning and then were
randomized to either continued depletion, 10% of full sup-
plementation (33 mg/l ascorbic acid), or full supplementation
(330 mg/l ascorbic acid). Each group contained 10 animals.
Lewis lung carcinoma cells were collected fromexponential
growth phase culture, washed twice, and then resuspended in
PBS (1 107 cells/ml). Groups of Gulo/ mice were injected
subcutaneously in the right flank with 0.1 ml of cell suspension
(1  106 cells). Tumor measurements were started with the
appearance of established tumors measuring 150 mg (be-
tween 5 and 7 days after implantation). After the initial ap-
pearance, tumors were measured with microcalipers every
2 days, and tumor masses were calculated using the for-
mula: [(width in mm)2  (length in mm)] / 2 [16]. When tumor
volume had reached 10% of body weight, animals were
euthanized using carbon dioxide narcosis and tumors were
removed and fixed in 10% formaldehyde for further analyses.
All data are expressed as the mean ± SD of three experi-
ments. Statistical significance was assessed by two-sample
t-test (independent variable).
Ascorbic Acid Measurements
Ascorbic acid concentrations in plasma samples were
measured by the 2,2V-dipyridyl method [17].
Protein Extraction and Western Blot Analysis
Cells were treated with 0.25% trypsin–EDTA, washed in
PBS, and lysed in 2 RIPA buffer. Protein samples were sep-
arated by 12.5% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and transferred to a PVDF membrane.
Membranes were blocked in TBS–Tween-20 (1%) containing
5% milk. Mouse monoclonal anti–HIF-1 antibody (1:500;
Novus Biologicals, Littleton, CO) and mouse anti–b-actin
(1:5000; Sigma) were resuspended in 10 ml of TBS–Tween-
20 (5% milk) and incubated with the membrane for 1 hour.
The secondary antibodies usedwere rabbit anti-mouse or goat
anti-mouse HRP-conjugated (1:8000; Pierce Biotechnology,
Rockford, IL).
Histology and Immunohistochemistry
Five-micrometer sections of formalin-fixed and paraffin-
embedded tumor tissues were treated with xylene to remove
paraffin and then rehydrated. Hematoxylin–eosin staining
andMasson’s trichrome staining for collagen were performed
using standard procedures. For immunohistochemical stain-
ing, deparaffinized and rehydrated sections were blocked
by incubation with serum blocking buffer for 30 minutes
at room temperature. Tissue sections were incubated for
1 hour with rabbit anti-mouse von Willebrand factor (vWF)
antibody (1:500; Dakocytomation, Carpinteria, CA) or mouse
monoclonal anti–HIF-1a (1:250; Novus Biologicals) for the
detection of vWF and HIF-1a, respectively. The sections
were then incubated with biotinylated goat anti-rabbit (for
vWF) or rabbit anti-mouse IgG (for HIF-1a) for 30 minutes
(1:500; Vector Laboratories, Burlingame, CA) and devel-
oped with an avidin–biotin peroxidase reaction using 3,3V-
diaminobenzidine tetrahydrochloride as chromogen. After
counterstaining with Mayer’s hematoxylin (Sigma), the
sections were dehydrated and coverslips were attached
with Permount (Fisher Scientific, Pittsburgh, PA). Appropriate
negative controls (by omission of the primary antibody)
were used. Anti–HIF-1a antibody functionality and speci-
ficity were confirmed by Western blot analysis using Lewis
lung carcinoma cells exposed to hypoxia for 16 hours as
positive control.
Quantitative immunohistochemistry imaging analyses
were performed using TIFFalyzer on images acquired by a
digital RGB camera (DXM 1200F; Nikon, Tokyo, Japan) and
saved in TIFF format [18,19]. All data are expressed as the
mean ± SD of three experiments. Statistical significance was
assessed by two-sample t-test (independent variable).
Results
Type IV Collagen Secretion By Endothelial Cells Requires
Ascorbic Acid
To test whether type IV collagen secretion by endothelial
cells requires ascorbic acid, we pulsed cultured HUVECs
with 0 to 200 mM ascorbic acid and then examined the plates
for the presence of immunoreactive type IV collagen using
an ultrasensitive ELISA. We found that HUVECs produced
type IV collagen in the absence of added ascorbic acid, but
that the addition of ascorbic acid increased type IV collagen
secretion. The culture medium (EGM) contains approxi-
mately 5 mM ascorbic acid, which may be sufficient to allow
for the observed type IV collagen secretion in the absence of
added vitamin C. The concentration of added ascorbic acid
that maximized collagen type IV accumulation (25 mM) is
approximately 50% below the physiological concentration of
ascorbic acid in healthy humans and mice (Figure 1A).
Finally, we should note that the collagen detected by this
ELISA was not necessarily stabilized type IV collagen
triple helix.
Endothelial Cell Migration and Tube Formation Require
Ascorbic Acid
Deposition of mature collagen type IV is essential for
endothelial cell migration and forms a scaffold for new blood
vessel formation. The importance of collagen type IV in
angiogenesis is further emphasized by evidence that inhibi-
tors of proline hydroxylation impair angiogenesis in vitro [20].
Migration and tube formation on the basement membrane
matrix mimic blood vessel formation, and we speculated
that restriction of ascorbic acid would limit migration and
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tube formation. We cultured HUVECs on Matrigel in EGM
containing 0 to 200 mM added ascorbic acid and examined
the cells for tube formation by light microscopy (Figure 1B).
Alignment of HUVECs into tube-like structures began within
2 to 4 hours and was completed by 18 hours. Very few in-
tact tubes were formed in 0 to 12.5 mM added ascorbic
acid (despite the estimated 5-mM background ascorbic acid
in the medium). As the concentration of ascorbic acid was
increased, greater numbers of intact tubes were observed,
reaching a maximum at 50 to 100 mM (23 ± 1.5 and 27.6 ±
2 tubes, respectively, per40 high-power field). Interestingly
and for unknown reasons, we observed decreased numbers
of intact tubes at supraphysiologic concentrations of ascorbic
acid (Figure 1C).
Restriction of Dietary Ascorbic Acid Depletes Plasma
Ascorbic Acid in Gulo/ Mice
Restriction of vitamin C in the diet of Gulo/ mice has
previously been demonstrated to deplete plasma ascorbic
acid [15]. We sought to confirm this finding in our animals
before embarking on experiments with tumor growth. We
measured plasma ascorbic acid concentrations in Gulo/
mice before limiting dietary ascorbic acid and at weekly
intervals after starting restriction until the animals were
euthanized. We found a gradual decrease in the concentra-
tion of plasma ascorbic acid over the 4 weeks of restriction
from a baseline concentration of 7.35 ± 0.6 mg/ml (approxi-
mately 42 mM) to 0.73 ± 0.1 mg/ml by 4 weeks when the
animals were fed only a diet containing 110 mg/kg ascorbic
acid without further supplementation. We observed only a
small further decline in the concentration of plasma ascorbic
acid in restricted Gulo/ mice over the course of tumor
growth (0.47 ± 0.12 mg/ml by 6 weeks) (Figure 2A).
Restriction of Dietary Ascorbic Acid Suppresses Tumor
Growth in Gulo/ Mice In Vivo
Our findings that endothelial cell migration and tube for-
mation require the presence of physiological concentrations
of ascorbic acid supported the generally accepted idea that
vitamin C is required for effective blood vessel formation
in vivo. To determine whether suppression of angiogenesis
by a scorbutic state would limit tumor growth, we used the
highly angiogenic tumor Lewis lung carcinoma in Gulo/
mice. Before starting our experiments, we first sought to
examine the survival and proliferation of Lewis lung carci-
noma cells in vitro in the absence of added ascorbic acid in
the medium. We found that the cells survived and demon-
strated no significant differences in growth from cells cultured
in the presence of added ascorbic acid (data not shown).
To study the effect of ascorbic acid restriction on initial
tumor outgrowth, animals were depleted of ascorbate for
4 weeks and then implanted subcutaneously with Lewis
lung carcinoma cells. After implantation, depleted animals
were either: 1) continued on a depleted diet (D), or 2) made
replete with ascorbic acid (D/R). We also included a group
of Gulo/ animals maintained on full supplementation be-
fore and after tumor implantation (R) (n = 10 in all groups).
We followed tumor volumes from appearance until the
point at which tumor burden necessitated euthanization.
At 12 days of growth after tumor appearance, tumors in
the depleted animals were significantly smaller than either
in depleted/replete groups or in fully supplemented groups
(D, 332.4 ± 67.3 mm3; D/R, 2992.6 ± 248 mm3; R, 1703 ±
316.4 mm3; P < .005 in D versus either D/R or R at 12 days;
n = 10 for all groups) (Figure 2B). Interestingly, tumors in
the depleted/replete mice were significantly larger than
those in animals maintained on ascorbic acid before and
after tumor implantation.
We then examined the effects of ascorbic acid depletion
on the growth of previously established tumors. For this, we
implanted Lewis lung carcinoma cells in Gulo/ animals
maintained on 165 mg/l ascorbic acid in drinking water for
2 weeks before the start of the study. When tumors were
Figure 1. Immunoreactive type IV collagen and intact tube formation by
endothelial cells require the presence of a physiological concentration of
ascorbic acid. Type IV collagen production by HUVECs in 0 to 200 Mascorbic
acid was measured by ELISA. (A) Representative photomicrographs of
tube formation onMatrigel basement membranematrix in 0 to 200 Mascorbic
acid (original magnification, 40). (B) Intact tubes formed on Matrigel in 0
to 200 M ascorbic acid were enumerated (original magnification, 40) (C).
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palpable, we randomized animals to ascorbic acid depletion
(D) or continued ascorbic acid supplementation of 165 mg/l
(R) (n = 10 in both groups). At 12 days of growth, we found
that tumors in the depleted group were significantly smaller
than those in the replete group (D, 744.3 ± 198.4 mm3;
R, 1934.7 ± 384 mm3; P < .005; n = 10) (Figure 2C).
As observed in previous studies, depletion of ascorbic
acid beyond approximately 6 weeks in homozygous Gulo/
mice led to weight loss and decreased activity with the on-
set of hemarthroses and petechial bleeding. We therefore
sought to test whether minimal supplementation of ascorbic
acid would delay the onset of scorbutic symptoms while
still retarding tumor growth. Following depletion of ascorbic
acid for 4 weeks in Gulo/ mice, we randomized animals
to either continued depletion (D), 10% of the full supple-
mentation dose (33 mg/l ascorbic acid) (10%), or full supple-
mentation (330 mg/l ascorbic acid) (R), and implanted
Lewis lung carcinoma cells subcutaneously in all the ani-
mals. We followed tumor growth from the time of appearance
up to 10 days of growth and found that tumors in the D group
and in the 10% supplemented group were both signifi-
cantly smaller than those in the fully supplemented group
(D, 800 ± 92.9 mm3; 10% of full supplementation, 776 ±
270 mm3; R, 2529 ± 562 mm3; P < .05 for D and 10% of
full supplementation versus R; n = 10) (Figure 2D). Impor-
tantly, the mice on the 10% ascorbic acid diet did not exhibit
weight loss or bleeding (data not shown).
Tumors from Animals on Low-Ascorbic-Acid Diets Are
Hemorrhagic and Show Decreased Capillary Density
We speculated that the differences we observed in tumor
size between ascorbic acid–restricted and supplemented
animals were due to inadequate delivery of essential nu-
trients as a result of poor blood vessel formation. To exam-
ine this, we first stained sections of representative tumors
from depleted and replete mice with Masson’s trichrome to
Figure 2. Tumor growth is significantly reduced in Gulo/ mice on restricted ascorbic acid. Plasma ascorbic acid concentrations in Gulo/ mice were measured
before and at weekly intervals following depletion of ascorbic acid and during tumor growth for 6 weeks (n = 7 in all groups). (A) Lewis lung carcinoma cells were
injected subcutaneously into Gulo/ mice depleted of ascorbic acid for 4 weeks following which animals were either continued on a depleted diet (D) or a replete
diet (D/R). A control group of Gulo/ mice was fully supplemented with ascorbic acid before and after injection with Lewis lung carcinoma cells (R). Tumors were
measured with microcalipers on indicated days (n = 10 per group). (B) Gulo/ mice implanted with Lewis lung carcinoma cells were randomized to ascorbic acid
depletion (D) or full repletion (R) when tumors were visible, and tumors were measured with microcalipers on indicated days (n = 10 per group). (C) Gulo/ mice
depleted of ascorbic acid were implanted with Lewis lung carcinoma cells and, when tumors were palpable, were randomized to depletion (D), 10% repletion (10%),
or 100% (R) repletion, and tumors were followed for 10 days (n = 10 per group) (D).
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determine the character of the tumor vasculature. The vascu-
lature in tumors excised from the depleted/replete (D/R) group
was well defined (Figure 3, A and C). In contrast, tumors in
depleted animals showed multiple areas of hemorrhage and
poorly formed blood vessels (Figure 3,B andD). Furthermore,
the absolute number of blood vessels was markedly reduced
in depleted tumors in comparison with that in tumors from
fully supplemented animals (blood vessels per 100 high-
power field: D, 5 ± 2; D/R, 18.6 ± 3; R, 25 ± 5; P < .005).
To further evaluate blood vessel development and to
enumerate capillaries, we stained tumors from depleted
and replete animals with an antibody specific for vWF—a
marker of mature endothelial cells [21,22]. We observed
increased vWF staining indicative of endothelial cells in
Figure 3. Tumors in ascorbic acid– restricted Gulo/ mice exhibit poorly formed vasculature with multiple hemorrhagic foci. Tissue sections from representative
tumors in replete (A, C, E, and G) and depleted (B, D, F, and H) Gulo/ mice were examined for vasculature after staining with Masson’s trichrome (MT) stain
(A and C), anti-vWF polyclonal antibody (vWF; E and F), or preimmune rabbit serum (ISO; G and H). Endothelial cells stained with a-vWF are in brown and shown
by arrows (A and B: original magnification, 200; C–H: original magnification, 400).
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tumor sections from the depleted/replete group of mice
(Figure 3E ) in comparison to minimal staining in depleted
tumors (Figure 3F ).
Ascorbic Acid Restriction Limits Collagen
Synthesis in Tumors
Because ascorbic acid is required for the action of prolyl
hydroxylase and, hence, collagen stabilization, we expected
that collagen staining in tumors excised from mice on re-
stricted ascorbic acid would be decreased. We stained rep-
resentative tissue sections from all groups with Masson’s
trichrome and found decreased collagen staining in the
fibrotic sheath of the depleted group in comparison with that
in the replete group (Figure 4).
Ascorbic Acid Restriction Does Not Affect HIF-1a
Protein Expression
As mentioned in the Introduction, ascorbic acid acts as a
cofactor in HIF proline hydroxylation by prolyl hydroxylase,
which promotes proteosomal destruction of HIF. In vitro
studies have demonstrated that physiological concentrations
of ascorbic acid suppress HIF-1a levels in transformed cells
[14]. Extrapolating from these results, it would be possible
that lack of HIF hydroxylation (secondary to ascorbic acid
deficiency) might slow its proteosomal destruction and in-
crease its intracellular levels. However, staining of tissue
sections of tumors with an anti–HIF-1a antibody did not
show differences in HIF-1a expression. The function and
specificity of this antibody were confirmed by a band at
120 kDa by Western blot analysis in Lewis lung carcinoma
cells exposed to hypoxia (data not shown). In addition,
quantitative immunohistochemical analyses of tumor sec-
tions in depleted and replete groups, in comparison with iso-
type control sections, did not reveal a significant difference in
HIF-1a expression (HIF-1a in replete tumors, 490 ± 118.0 vs
487 ± 28.3 energy units/pixel in ascorbic acid–depleted
tumors). Therefore, at least in the in vivo environment, ascor-
bic acid depletion may selectively suppress tumor blood ves-
sel formation/stability without affecting HIF levels (Figure 5).
Discussion
The importance of vitamin C in carcinogenesis and tumor
growth has been the subject of controversy for years. Early
observational clinical studies demonstrated a 10% re-
gression rate [23] and up to a 20-fold increase in survival in
patients with advanced cancer treated with high-dose ascor-
bic acid (10 g/day intravenously for 10 days, followed by oral
administration of the same dose) in comparison to controls
retrospectively analyzed from a population of similar terminal
cancer patients [24,25]. The results of these studies were
widely disputed, in part due to lack of randomization. Two sub-
sequent randomized placebo-controlled double-blinded trials
using oral vitamin C [26,27] demonstrated no improvement
in survival in patients treated with high doses of ascorbic acid.
Perhaps as a result, the use of megadoses of vitamin C as
a possible therapy for cancer fell by the wayside and has not
been revisited until recently [28,29].
The present work was based on precisely the opposite
hypothesis: that restriction of the availability of ascorbic acid
would suppress tumor growth, perhaps through diminishing
angiogenesis. Ascorbic acid plays an essential role in angio-
genesis as a cofactor for prolyl hydroxylase in catalyzing
hydroxyproline synthesis [7]. Hydroxyproline is required for
Figure 4. Collagen synthesis is decreased in subcutaneous tumors formed in Gulo/ mice on an ascorbic acid– restricted diet. Sections from representative
tumors harvested from replete (A and C) and depleted (B and D) Gulo/ mice were evaluated for collagen after staining with Masson’s trichrome. Collagen
appears as blue-stained fibrillar material indicated by arrows (A and B: original magnification, 200; C and D: original magnification, 400).
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effective type IV collagen production by endothelial cells.
Collagen type IV forms a critical part of the vascular base-
ment membrane and is vital for new blood vessel formation.
Tumor growth and metastasis are dependent on angio-
genesis. One early study demonstrated that tumor growth
in the avascular anterior chamber of the rabbit eye was ar-
rested at a small size (f 1 mm3) due to the absence of neo-
vascularization, whereas tumors grew readily on the surface
of the iris where new vasculature could develop [30]. Tumors
secrete angiogenic growth factors such as VEGF, which
promote endothelial cell proliferation and new blood vessel
development [31]. That anti-VEGF antibodies and a domi-
nant interfering form of the VEGF receptor 2 (flk-1) have
proven to be successful in impairing neovascularization and
in causing tumor regression demonstrates the importance
of angiogenesis in tumor growth [32,33].
An early study on the importance of ascorbic acid in
angiogenesis was carried out in guinea pigs, which, like pri-
mates and Gulo/ mice, are incapable of vitamin C synthe-
sis. In subcutaneously implanted polyvinyl sponges (which
promote angiogenic activity), investigators found dilated
blood vessels, interstitial hemorrhage, and disintegration of
connective tissues in scorbutic guinea pigs [34,35]. A later
investigation demonstrated decreased type IV collagen
mRNA in blood vessels in the presence of restricted ascorbic
acid [35]. In addition, inhibitors of prolyl hydroxylase (e.g.,
ciclopirox and 2,2V-dipyridyl) cause inhibition of both tube
formation on Matrigel and aortic arch sprouting in vitro [20].
Similarly, proline analogs such as cis-hydroxyproline, which
impair a helix formation and collagen secretion, lead to the
formation of large and dilated blood vessels in a plasma clot
culture model [36] and inhibit angiogenesis in chick chorioal-
lantoic membranes [37]. These earlier observations are in
accord with our in vitro data from cultured HUVECs showing
a requirement for ascorbic acid for both type IV collagen
synthesis and endothelial tube formation on a basement
membrane matrix. Our data indicate that although tube
formation is maximal at concentrations of ascorbic acid that
correspond to physiological concentrations, supraphysio-
logic concentrations appear to retard endothelial cell migra-
tion and tube formation. In contrast, type IV collagen was not
affected by supraphysiologic ascorbic acid.
Our experiments in homozygous Gulo/ mice indicate
that dietary ascorbic acid restriction in these mice retards
both initial tumor outgrowth and the growth of previously es-
tablished tumors. Histopathological data from tumors in
ascorbic acid–restricted mice demonstrate a paucity of
blood vessels (from both microscopic examination and stain-
ing for vWF) and areas of hemorrhage. In contrast, tumors
grown in mice supplemented with ascorbic acid have nu-
merous and well-defined blood vessels and few areas of
hemorrhage. Collagen staining of tumors in ascorbic acid–
deficient and ascorbic acid–replete mice also suggests that
collagen synthesis in these tumors is affected by dietary
restriction of vitamin C. The possibility of using ascorbic acid
restriction clinically is supported by our observation that
restricting ascorbic acid to 10% of the full supplementation
dose delays the onset of scorbutic symptoms inGulo/mice
while still significantly retarding tumor growth. Interestingly,
we observed a trend toward increased tumor growth in mice
that had been depleted of and then made replete with
ascorbic acid. We postulate that host support for tumor
growth may be increased secondary to overcompensation
after ascorbic acid depletion. For example, tumor-associated
endothelial cells may have upregulated surface trans-
porters in response to low extracellular ascorbic acid, and
this overexpression may confer the capacity for increased
angiogenesis. However, the precise mechanism(s) for this
Figure 5. HIF-1a protein expression is similar in tumors from replete Gulo/ animals and tumors from depleted Gulo/ animals. Tissue sections from representa-
tive tumors in replete (A and C) and depleted (B and D) Gulo/ mice were examined by immunohistochemistry using an anti –HIF-1a mouse monoclonal antibody
(A and B) or preimmune mouse serum (C and D) (original magnification, 400). Arrows indicate representative areas of HIF-1a expression.
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observation is not obvious, and we intend to examine this
phenomenon in a future study.
This is, by no means, the first attempt to modify tumor
growth through depletion of ascorbic acid. One early study
reported the effects of ascorbic acid depletion on the growth
and biology of sarcomas initiated by 20-methylcholanthrene
in guinea pigs [38]. These investigators found that animals
given high doses of ascorbic acid showed accelerated tumor
growth, whereas tumors grew slowly (or even regressed) in
guinea pigs fed a scorbutic diet. However, other studies in
guinea pigs have provided conflicting results regarding the
requirements for ascorbic acid in collagen synthesis [35,39],
making interpretation of the effects of ascorbic acid depletion
on tumor growth in guinea pigs difficult.
A recent study by Parsons et al. [40] evaluated tumor
growth in a mammary tumor model in Gulo/mice bred in a
Balb/c background. In these experiments, mice were ascor-
bic acid–depleted for 2 weeks before tumor implantation and
did not show any differences in tumor growth in comparison
with control animals on full ascorbic acid supplementation.
We cannot, with certainty, explain why these results are so
divergent from those reported here, but differences in tumor
type and/or regimen used to deplete ascorbic acid might be
involved. In our experiments, we restricted dietary ascorbic
acid for 4 weeks so that the serum ascorbic acid concentra-
tion decreased to approximately five-fold below the normal
physiological range. Furthermore, we chose to study Lewis
lung carcinoma because this tumor relies heavily on angio-
genesis [41,42]. Finally, strain differences in mice used in
each study may also have affected the outcomes reported.
Tumors have been found to have an unusual metabolism
of ascorbic acid, actively concentrating ascorbic acid relative
to surrounding normal fluids and tissues [43,44]. This occurs
across a concentration gradient, and uptake appears to
involve the oxidized form dehydroascorbic acid, which enters
through facilitative glucose transporters (GLUTs) [45]. In cer-
tain malignant cell types (e.g., melanoma), dehydroascorbic
acid uptake may be up to 10 times greater than that exhibited
by normal melanocytes [44]. However, despite evidence
demonstrating that ascorbic acid is concentrated by cancer
cells, the precise function performed by vitamin C in tumor
cells is far from clear. In U937 lymphoma cells, ascorbic acid
was reported to decrease Fas pathway-mediated apoptosis
[46], and similar findings have been made on apoptosis
engendered by the NFnB pathway in several other tumor cell
lines [47]. Furthermore, pretreatment of cells with the readily
transported form of ascorbic acid, dehydroascorbic acid, has
been shown to decrease radiation-induced apoptosis in HL60
promyelocytic leukemia cells [48]. These data indicate that
ascorbic acid, in addition to supporting angiogenic activities,
may also promote tumor cell survival and protect against
oxidative stress.
Ascorbic acid depletion may lead to stabilization of HIF-1a
and thus contribute to tumor growth through factors down-
stream of HIF such as VEGF and GLUT-1, thus increasing
angiogenesis and glycolysis [14]. Surprisingly, our immuno-
histochemical analyses of tumors demonstrated that HIF-1a
expression was not significantly altered by the absence of
ascorbic acid. These data indicate that ascorbic acid deple-
tion may preferentially affect collagen formation—and, thus,
new vessel formation—without affecting HIF-1a stability.
Our results, although obtained with a single mouse model
and a single type of implantable tumor, support the idea that
ascorbic acid depletion powerfully restricts tumor growth
in vivo, likely through interference with angiogenesis. Recent
reports continue to advocate an increase in ascorbic acid
intake over the recommended daily allowance for optimal
reduction of the risk of cancer and chronic disease [49]. At the
least, our results suggest that ascorbic acid supplementation
in patients with cancer should be reevaluated. Additionally,
we believe that decreasing dietary ascorbic acid or disrupt-
ing prolyl hydroxylases may provide novel therapeutic ap-
proaches to the treatment of cancer.
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